Stressgen (VSE: SSB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pied Piper who wrote (95)	10/14/1999 6:20:00 PM
From: Heat Shock	Read Replies (1) of 236

To all: huge upgrade in indication from phase I to phase II. From the PR on 3rd Qtr results: biz.yahoo.com During the quarter, the Company completed a Phase I safety trial for HspE7 in healthy male and female volunteers. The data from this study may assist StressGen in starting two Phase II clinical trials before the end of 1999. The clinical indications are expected to be anal dysplasia and invasive cervical cancer. Invasive cervical cancer! I have only followed biotech for a few years, but I do not recall any case where a P1 indication was a very early stage of a disease process(cervical dysplasia- warts) and the P2 indiction was a very late stage (invasive cervical cancer). Heat

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next